<DOC>
	<DOCNO>NCT00102609</DOCNO>
	<brief_summary>The purpose study determine dose combination trabectedin ( Yondelis ) Doxorubicin neutropenia ( low white blood cell count ) could manage filgrastim ( Granulocyte-Colony Stimulation Factor use help control neutropenia ) patient type cancer call soft tissue sarcoma .</brief_summary>
	<brief_title>A Safety Study Utilizing Yondelis Doxorubicin Patients With Type Cancer Called Soft Tissue Sarcoma</brief_title>
	<detailed_description>This multicenter , open-label ( identity assign study treatment know patient study staff ) study determine dose combination trabectedin ( Yondelis ) Doxorubicin neutropenia ( low white blood cell count ) manageable use filgrastim ( agent use manage neutropenia ) associate clinically acceptable number side effect severe enough continuation treatment patient recurrent persistent soft tissue sarcoma ( STS , malignant tumor attack body 's infrastructure fat , muscle , nerve , joint , blood vessel , deep skin tissue ) . Patients enrol study study-specific entry criterion meet informed consent obtain . Patients required attend regular clinic visit receive study medication status monitor . A detailed explanation provide study physician ( Investigator ) conduct study . Doxorubicin ( 50 75 mg/m2 ) give 10-15 minute intravenous ( i.v . ) infusion Day 1 via central venous catheter tube place large vein . Trabectedin ( 0.9 1.3 mg/m2 ) give 3 hour i.v . infusion , immediately follow administration doxorubicin . Dexamethasone 20 mg give within 1 hour start doxorubicin i.v . infusion filgrastim administer accord manufacturer 's instruction .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neoplasms Histologic Type</mesh_term>
	<mesh_term>Neoplasms , Connective Soft Tissue</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Have diagnosis soft tissue sarcoma , recurrent persistent Signed informed consent obtain patient perform studyrelated procedure Patients treat 1 prior chemotherapy regimen ( include adjuvant ( additional ) therapy ) Previous exposure anthracyclines ( class drug use cancer chemotherapy , example Doxorubicin ) trabectedin Less 4 week since radiation therapy Known metastasis ( spread ) cancer central nervous system Other ongoing serious illness present time enrollment determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Doxorubicin</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Yondelis</keyword>
	<keyword>Ecteinascidin 743</keyword>
	<keyword>Filgrastim , Antineoplastic</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Alkylating Agents</keyword>
</DOC>